Can a diabetes drug slow cellular aging?
Henagliflozin (an SGLT2 inhibitor) lengthens telomeres in a small 6 month RCT… interesting, but not one for your longevity protocol just yet.
In a new multicentre, randomised, double‑blind, placebo‑controlled trial, 142 adults aged 35–70 with type 2 diabetes were given either henagliflozin 10 mg daily or a placebo for 26 weeks, alongside structured lifestyle advice for everyone. Researchers focused on leukocyte telomere length (a marker often linked to cellular ageing), measured by qPCR T/S ratio, to see how it changed over the study period. By 26 weeks, 90.5% of people taking henagliflozin showed telomere lengthening, compared with 65.6% in the placebo group. The average difference in telomere change between groups was modest (around +0.06 in T/S ratio) but statistically significant, suggesting a real, if small, effect. Beyond telomeres, henagliflozin also improved glycaemic control and favourably influenced some IGF‑1 system markers and immune parameters, pointing to a broader metabolic and immune impact in people with type 2 diabetes.
My take: While the study has good internal validity (randomised, double‑blind, controlled), the small sample, short duration, and a single surrogate biomarker primary endpoint mean this is promising but not ready for primary prevention.
The study was conducted in people with type 2 diabetes, where SGLT2 inhibitors already improve hard outcomes so it’s not generalisable to healthy individuals. Telomere length is one imperfect biomarker among many, and short‑term changes do not prove slower biological aging overall. Nothing really practice-changing here but…
For patients/clinicians: For those type 2 diabetes who already meet guideline criteria for SGLT2i (e.g., CVD, CKD, heart failure), you can honestly frame these drugs as cardio‑renal‑metabolic therapies that may also have favourable effects on some aging markers.
SGLT2 inhibitors solely for “anti‑aging” in metabolically healthy people; risks include genital infections and rare ketoacidosis, with no evidence of lifespan or healthspan extension in this group.
Source: Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: a multicenter, randomized, double‑blind, placebo‑controlled study. Cell Reports Medicine. 2025.
#longevity #healthspan #longevitymedicine #antiaging #biologicalaging #telomere #telomerelength #agingbiomarkers #cellularaging #SGLT2inhibitor #henagliflozin #diabetes #type2diabetes #diabetesmanagement #cardiometabolic #cardiometabolichealth #kidneyhealth #heartfailure #evidencebasedmedicine #clinicalresearch #medicalresearch #endocrinology #diabetology #pharmacology #preventivemedicine #pharma #clinicaltrials #CellReportsMedicine #agingresearch
